Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
- Primary vaccination with Beta-containing vaccine candidate delivers 64.7% efficacy against symptomatic infection in adults, and 75.1% efficacy in participants previously infected with COVID-19Article Summary
- Sequencing analysis has shown 72 percent efficacy against Omicron in adults overall and 93.2 percent in seropositives.
- Favorable safety and tolerability profile
- First-ever efficacy findings in an Omicron setting indicate the need for a vaccine that contains beta.
GSK plc and Sanofi publish encouraging results from a vaccine trial that examined an adjuvanted bivalent D614 and beta (B.1.351) vaccine candidate. The vaccine from Sanofi-GSK is the first candidate to show effectiveness in a trial with a controlled placebo in a setting with high Omicron variant circulation. The potential vaccine has a good safety and tolerability profile.
The COVID-19 booster vaccine candidate from Sanofi, which is based on the Beta variant antigen and contains GSK’s pandemic adjuvant, has undergone two clinical trials. Earlier this month, Sanofi released good results from these trials. The possibility of Sanofi-next-generation GSK’s Beta-based booster to be an appropriate response to public health demands is strongly suggested by these statistics when taken collectively.
Throughout Stage 1 and Stage 2 of the VAT08 trial (~23,000 participants in total), the Sanofi-GSK vaccine demonstrated a favorable safety and tolerability profile.
These initiatives are supported by federal funds from the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, and the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, under Contract # W15QKN-16-9-1002 and the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense at the U.S. Department of Defense (NIAID).